水飞蓟宾葡甲胺片对抗神经病药所致肝损伤的疗效及安全性评价

Safety and efficacy of Silibin Meglumine tablets in treatment with liver injury induced by anti neuropathy

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2016, 43(5)
作者
作者单位

北京市昌平区中西医结合医院感染科 ;
北京市昌平区中西医结合医院精神病区 ;
北京市昌平区中西医结合医院功能科 ;
北京市昌平区中西医结合医院 内分泌科 ;
北京市昌平区中西医结合医院 妇产科 ;

摘要
【摘要】目的:探讨水飞蓟宾葡甲胺片对抗神经病药所致肝损伤的疗效及安全性。方法:将2014年1月至2015年1月医院收治的128例服用抗精神分裂症药物所致肝损伤患者按照随机数字表法分为观察组64例和对照组64例,观察组口服水飞蓟宾葡甲胺片,200mg/次,3次/d;对照组口服护肝宁片,1.75g/次,3次/d,两组患者治疗3个月为1个疗程。分别于治疗前、1个月、3个月、6个月检测两组患者肝功能血清酶学指标和尿素氮(BUN)、肌酐(Cr)水平,并纪录两组患者临床症状改善情况及不良反应发生率。结果:观察组总有效率为93.8%(60/64),对照组总有效率为89.1%(57/64),两组患者总有效率比较差异无统计学意义(P>0.05)。两组治疗前后TBIL比较差异无统计学意义(P>0.05),治疗后ALT、AST、γ-GT均呈降低趋势,治疗1个月、3个月观察组ALT、AST、γ-GT显著低于同时段对照组(P<0.05)。两组患者治疗前后BUN比较差异无统计学意义(P>0.05),治疗后Cr呈降低趋势,其中治疗1个月、3个月、6个月观察组Cr显著低于同时段对照组(P<0.05)。治疗6个月后,观察组肝区不适、肝大发生率显著低于对照组(P<0.05),两组患者乏力、纳差、腹胀等临床症状发生率比较差异无统计学意义(P>0.05)。结论:水飞蓟宾葡甲胺片和护肝宁片均能改善抗神经病药所致肝损伤患者肝功能,水飞蓟宾葡甲胺片降酶速度更快,对临床症状改善作用更明显,且安全性高,值得临床推广。
Abstract
[Abstract] Objective: To explore the safety and efficacy of Silibin Meglumine tablets in treatment with liver injury induced by anti neuropathy.Methods: A total of 128 cases of liver injury patients who induced by anti neuropathy accorded to the random number table method was divided into observation group 64 cases and control group 64 cases,observation group was treated with Silibin Meglumine tablets, 200mg/times, 3 times/d.Control group oral Huganning tablets,1.75g/times, 3 times/d, two groups of patients were treated 3 months for 1 courses.Liver function and blood urea nitrogen (BUN) and creatinine (Cr) levels were monitored in two groups of patients before and after 1 months, 3 months and 6 months of treatment respectively,and clinical symptoms,adverse reactions incidence of two groups were recoreded.Results:The total effective rate of observation group was 93.8% (60/64), the control group total effective rate was 89.1% (57/64), there was no significant difference in the total effective rate between the two groups (P>0.05).There was no significant difference in TBIL between the two groups before and after treatment (P>0.05),after treatment two groups ALT, AST, γ-GT showed a decreased trend,and after 1 months and 3 months the ALT, AST, γ-GT in observation group of treatment was significantly lower than those in the control group in same period(P<0.05).There was no significant difference in BUN between the two groups before and after treatment (P>0.05),after treatment two groups Cr showed a decreased trend,and after 1 months and 3 months the Cr in observation group was significantly lower than those in the control group in same period(P<0.05).After 6 months of treatment, the incidence of uncomfortable in the hepatic region,large hepatic in the observation group was significantly lower than that in the control group (P<0.05),two groups of patients with fatigue, anorexia, abdominal distension with no significant differences (P>0.05).Conclusion:Silibin Meglumine tablets and Huganning tablets can improve liver function in patients with liver injury induced by anti neuropathy,Silibin Meglumine tablets reduces AST,ALT level are faster, clinical symptoms improvement are more obvious, with high safety,and worthy of clinical promotion.
关键词
【关键词】水飞蓟宾葡甲胺;精神分裂症;抗神经病药;药物性肝损伤
KeyWord
[Key words]Silybin meglumine; Schizophrenia; Antipsychotic drug; Drug induced liver injury
基金项目
页码 839-841
  • 参考文献
  • 相关文献
  • 引用本文

徐浩*,张国玲,刘义,高蕾,肖玉凤. 水飞蓟宾葡甲胺片对抗神经病药所致肝损伤的疗效及安全性评价 [J]. 国际精神病学杂志. 2016; 43; (5). 839 - 841.

  • 文献评论

相关学者

相关机构